Oral administration of histone deacetylase inhibitor MS-275 Ameliorates neuroinflammation and cerebral amyloidosis and improves behavior in a mouse model

Journal of Neuropathology and Experimental Neurology

Volumn 72, Issue 3, 2013, Pages 178-185

  Zhang, Zhi Yuan ^a   Schluesener, Hermann J ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Alzheimer disease; APP PS1 transgenic mouse; Cerebral amyloidosis; HDAC inhibitor; MS 275; Neuroinflammation.

Indexed keywords

AMYLOID BETA PROTEIN; ENTINOSTAT;

ALZHEIMER DISEASE; AMYLOID PLAQUE; AMYLOIDOSIS; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASTROCYTE; BEHAVIOR CHANGE; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN DISEASE; CELL ACTIVATION; CELL VIABILITY; CEREBRAL AMYLOIDOSIS; CONTROLLED STUDY; DISEASE MODEL; ENCEPHALITIS; FEMALE; HIPPOCAMPUS; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MACROPHAGE; MALE; MICROGLIA; MOUSE; NESTING; NONHUMAN; PRIORITY JOURNAL; SOCIAL BEHAVIOR; TREATMENT DURATION;

ADMINISTRATION, ORAL; ALZHEIMER DISEASE; AMYLOIDOSIS; ANIMALS; BEHAVIOR, ANIMAL; BENZAMIDES; BRAIN; DISEASE MODELS, ANIMAL; HISTONE DEACETYLASE INHIBITORS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PYRIDINES;

EID: 84874661821     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e318283114a     Document Type: Article

References (49)

1. Herrmann N, Chau SA, Kircanski I, et al. Current and emerging drug treatment options for Alzheimer's disease: A systematic review. Drugs 2011;71:2031-65
2. Rangasamy T, Cho CY, Thimmulappa RK, et al. Genetic ablation of Nrf2 enhances susceptibility to cigarette smokeYinduced emphysema in mice. J Clin Invest 2004;114:1248-59
3. Selkoe DJ. Alzheimer's disease is a synaptic failure. Science 2002;298: 789-91
4. Akiyama H, Barger S, Barnum S, et al. Inflammation and Alzheimer's disease. Neurobiol Aging 2000;21:383-421
5. Wyss-Coray T, Mucke L. Inflammation in neurodegenerative diseaseVA double-edged sword. Neuron 2002;35:419-32
6. Martin-Moreno AM, Brera B, Spuch C, et al. Prolonged oral cannabinoid administration prevents neuroinflammation, lowers beta-amyloid levels and improves cognitive performance in Tg APP 2576 mice. J Neuroinflammation 2012;9:8
7. Govindarajan N, Agis-Balboa RC, Walter J, et al. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J Alzheimers Dis 2011;26:187-97
8. Xu K, Dai XL, Huang HC, et al. Targeting HDACs: A promising therapy for Alzheimer's disease. Oxid Med Cell Longev 2011;2011:143269
9. Stilling RM, Fischer A. The role of histone acetylation in age-associated memory impairment and Alzheimer's disease. Neurobiol Learn Mem 2011;96:19-26
10. Johnstone SE, Baylin SB. Stress and the epigenetic landscape: A link to the pathobiology of human diseases? Nat Rev Genet 2010;11:806-12
11. Lin HY, Chen CS, Lin SP, et al. Targeting histone deacetylase in cancer therapy. Med Res Rev 2006;26:397-413
12. Sananbenesi F, Fischer A. The epigenetic bottleneck of neurodegenerative and psychiatric diseases. Biol Chem 2009;390:1145-53
13. Saha RN, Pahan K. HATs and HDACs in neurodegeneration: A tale of disconcerted acetylation homeostasis. Cell Death Differ 2006;13:539-50
14. Abel T, Zukin RS. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol 2008;8:57-64
15. Fischer A, Sananbenesi F, Mungenast A, et al. Targeting the correct HDAC(s) to treat cognitive disorders. Trends Pharmacol Sci 2010;31: 605-17
16. Li Y, Yuan Z, Liu B, et al. Prevention of hypoxia-induced neuronal apoptosis through histone deacetylase inhibition. J Trauma 2008; 64:863-70
17. Zhang Z, Zhang ZY, Fauser U, et al. Valproic acid attenuates inflammation in experimental autoimmune neuritis. Cell Mol Life Sci 2008;65: 4055-65
18. Blanchard F, Chipoy C. Histone deacetylase inhibitors: New drugs for the treatment of inflammatory diseases? Drug Discov Today 2005;10: 197-204
19. Hess-Stumpp H, Bracker TU, Henderson D, et al. MS-275, a potent orally available inhibitor of histone deacetylasesVThe development of an anticancer agent. Int J Biochem Cell Biol 2007;39:1388-405
20. Lin HS, Hu CY, Chan HY, et al. Anti-rheumatic activities of histone deacetylase (HDAC) inhibitors in vivo in collagen-induced arthritis in rodents. Br J Pharmacol 2007;150:862-72
21. Zhang ZY, Zhang Z, Schluesener HJ. MS-275, an histone deacetylase inhibitor, reduces the inflammatory reaction in rat experimental autoimmune neuritis. Neuroscience 2010;169:370-77
22. Nencioni A, Beck J, Werth D, et al. Histone deacetylase inhibitors affect dendritic cell differentiation and immunogenicity. Clin Cancer Res 2007; 13:3933-41
23. Zhang ZY, Schluesener HJ. HDAC inhibitor MS-275 attenuates the inflammatory reaction in rat experimental autoimmune prostatitis. Prostate 2012;72:90-99
24. Ryan QC, Headlee D, Acharya M, et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005;23: 3912-22
25. Gengler S, Hamilton A, Holscher C. Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer's disease is impaired in old but not young mice. PLoS One 2010;5:e9764
26. Radde R, Bolmont T, Kaeser SA, et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep 2006;7:940-46
27. Moehlmann T, Winkler E, Xia X, et al. Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci USA 2002;99:8025-30
28. Wesson DW, Wilson DA. Age and gene overexpression interact to abolish nesting behavior in Tg2576 amyloid precursor protein (APP) mice. Behav Brain Res 2011;216:408-13
29. Zhang Z, Zhang ZY, Fauser U, et al. FTY720 ameliorates experimental autoimmune neuritis by inhibition of lymphocyte and monocyte infiltration into peripheral nerves. Exp Neurol 2008;210:681-90
30. Shahbazian MD, Grunstein M. Functions of site-specific histone acetylation and deacetylation. Annu Rev Biochem 2007;76:75-100
31. D'Mello SR. Histone deacetylases as targets for the treatment of human neurodegenerative diseases. Drug News Perspect 2009;22:513-24
32. Jia H, Pallos J, Jacques V, et al. Histone deacetylase (HDAC) inhibitors targeting HDAC3 and HDAC1 ameliorate polyglutamine-elicited phenotypes in model systems of Huntington's disease. Neurobiol Dis 2012; 46:351-61
33. Kidd SK, Schneider JS. Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neuroscience 2011;194:189-94
34. Kilgore M, Miller CA, Fass DM, et al. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010;35:870-80
35. Francis YI, Fa M, Ashraf H, et al. Dysregulation of histone acetylation in the APP/PS1 mouse model of Alzheimer's disease. J Alzheimers Dis 2009;18:131-39
36. Ricobaraza A, Cuadrado-Tejedor M, Marco S, et al. Phenylbutyrate rescues dendritic spine loss associated with memory deficits in a mouse model of Alzheimer disease. Hippocampus 2012;22:1040-50
37. Qing H, He G, Ly PT, et al. Valproic acid inhibits Abeta production, neuritic plaque formation, and behavioral deficits in Alzheimer's disease mouse models. J Exp Med 2008;205:2781-89
38. Venkataramani V, Rossner C, Iffland L, et al. Histone deacetylase inhibitor valproic acid inhibits cancer cell proliferation via down-regulation of the alzheimer amyloid precursor protein. J Biol Chem 2010;285: 10678-89
39. Simonini MV, Camargo LM, Dong E, et al. The benzamide MS-275 is a potent, long-lasting brain regionYselective inhibitor of histone deacetylases. Proc Natl Acad Sci USA 2006;103:1587-92
40. Tweedie D, Ferguson RA, Fishman K, et al. Tumor necrosis factor-alpha synthesis inhibitor 3,6'-dithiothalidomide attenuates markers of inflammation, Alzheimer pathology and behavioral deficits in animal models of neuroinflammation and Alzheimer's disease. J Neuroinflammation 2012;9:106
41. Adcock IM. Histone deacetylase inhibitors as novel anti-inflammatory agents. Curr Opin Investig Drugs 2006;7:966-73
42. Kim HJ, Rowe M, Ren M, et al. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: Multiple mechanisms of action. J Pharmacol Exp Ther 2007;321:892-901
43. Zhang B, West EJ, Van KC, et al. HDAC inhibitor increases histone H3 acetylation and reduces microglia inflammatory response following traumatic brain injury in rats. Brain Res 2008;1226:181-91
44. Glauben R, Sonnenberg E, Zeitz M, et al. HDAC inhibitors in models of inflammation-related tumorigenesis. Cancer Lett 2009;280: 154-59
45. Agostinho P, Cunha RA, Oliveira C. Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease. Curr Pharm Des 2010;16: 2766-78
46. Doherty GH. Nitric oxide in neurodegeneration: Potential benefits of non-steroidal anti-inflammatories. Neurosci Bull 2011;27:366-82
47. Patel NS, Paris D, Mathura V, et al. Inflammatory cytokine levels correlate with amyloid load in transgenic mouse models of Alzheimer's disease. J Neuroinflammation 2005;2:9
48. Graff J, Rei D, Guan JS, et al. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012;483:222-26
49. Alexander G, Hanna A, Serna V, et al. Increased aggression in males in transgenic Tg2576 mouse model of Alzheimer's disease. Behav Brain Res 2011;216:77-83